ATG-107

N/A

Report date: 2026/03/23 20:03:44

Base Information

Drug NameATG-107
Drug Alias NameATG-107ATG107
ClassificationBiologics > T cell engagersBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsTyrosine-protein kinase receptor FLT3 modulators
TargetsT cell surface glycoprotein CD3Tyrosine-protein kinase receptor FLT3
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesAntengene Corp Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAntengene Corp Ltd
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A